Literature DB >> 3767462

Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis.

J W Bijlsma, S A Duursma, O Huber-Bruning.   

Abstract

The deleterious effects of corticosteroids (CS) on bone are well known, but probably differ depending on duration and dosage of CS therapy. Presently huge amounts of CS are given over a short period of time in different rheumatic conditions. Not much is known about the effect of this kind of CS treatment on bone metabolism. Twenty patients with persistently active rheumatoid arthritis were treated with 1 g methylprednisolone (MP) three times on alternate days over a five day period. Twenty four hours after the first MP pulse serum calcium was increased and the values of parathyroid hormone and 1,25-dihydroxyvitamin D tended to increase. After the second MP pulse, however, these values had returned to the starting values. The urinary calcium excretion increased during MP pulse therapy and returned to the initial value immediately after the pulse therapy. The hydroxyproline excretion tended to decrease during therapy and stayed decreased immediately afterwards, indicating a decrease in bone resorption. It is concluded that bone metabolism is not seriously affected during MP pulse therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3767462      PMCID: PMC1001982          DOI: 10.1136/ard.45.9.757

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Effect of glucocorticoids on function of the parathyroid glands in man.

Authors:  R F Fucik; S C Kukreja; G K Hargis; E N Bowser; W J Henderson; G A Williams
Journal:  J Clin Endocrinol Metab       Date:  1975-01       Impact factor: 5.958

2.  Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture.

Authors:  W Y Au
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

Review 3.  Osteocytic osteolysis.

Authors:  L F Bélanger
Journal:  Calcif Tissue Res       Date:  1969-08-11

4.  Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.

Authors:  Y Suzuki; Y Ichikawa; E Saito; M Homma
Journal:  Metabolism       Date:  1983-02       Impact factor: 8.694

5.  Lack of influence of the anabolic steroid nandrolondecanoate on bone metabolism.

Authors:  J W Bijlsma; S A Duursma; R Bosch; O Huber
Journal:  Acta Endocrinol (Copenh)       Date:  1982-09

6.  A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease.

Authors:  I A Williams; E M Baylis; M E Shipley
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

7.  Short-term effect of prednisone on serum 1,25-dihydroxyvitamin D in normal individuals and in hyper- and hypoparathyroidism.

Authors:  J J Braun; J R Juttmann; T J Visser; J C Birkenhäger
Journal:  Clin Endocrinol (Oxf)       Date:  1982-07-01       Impact factor: 3.478

8.  Bone turnover in early rheumatoid arthritis. 1. Biochemical and kinetic indexes.

Authors:  P N Sambrook; B M Ansell; S Foster; J M Gumpel; R Hesp; J Reeve; J M Zanelli
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

9.  Pathogenetic role of 1 alpha,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy.

Authors:  J E Zerwekh; C Y Pak; R A Kaplan; J L McGuire; K Upchurch; N Breslau; R Johnson
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

10.  Relevance of urinary excretion of alcian blue-glycosaminoglycans complexes and hydroxyproline to disease activity in rheumatoid arthritis.

Authors:  J M Mbuyi; J Dequeker; M Teblick; M Merlevede
Journal:  J Rheumatol       Date:  1982 Jul-Aug       Impact factor: 4.666

  10 in total
  10 in total

Review 1.  Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?

Authors:  M D Smith; M J Ahern; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

2.  Corticosteroids and bone mass in asthma.

Authors:  D M Reid; J J Nicoll; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-30

Review 3.  Bone metabolism in patients with rheumatoid arthritis.

Authors:  J W Bijlsma
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

Review 4.  Glucocorticoid-induced osteoporosis: who to treat with what agent?

Authors:  René Rizzoli; Emmanuel Biver
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

5.  Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.

Authors:  W F Lems; M I Gerrits; J W Jacobs; R M van Vugt; H J van Rijn; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

6.  Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study.

Authors:  G Haugeberg; B Griffiths; K B Sokoll; P Emery
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

7.  Assessment of bone mineral density by dual x-ray absorptiometry in dermatological patients treated by corticosteroids.

Authors:  Dorria Salem; Soha Talaat; Mona R E Abdel-Halim; Kareem Mohammed Mohsen
Journal:  Indian J Dermatol       Date:  2010 Jul-Sep       Impact factor: 1.494

8.  Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis.

Authors:  M J van der Veen; J W Bijlsma
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

Review 9.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

10.  Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.

Authors:  Joanna Rymuza; Michał Popow; Zuzanna Żurecka; Jerzy Przedlacki; Tomasz Bednarczuk; Piotr Miśkiewicz
Journal:  Endocrine       Date:  2018-12-01       Impact factor: 3.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.